Latest Security News

Macquarie Technology Group Limited reported solid FY25 results with continued EBITDA growth and strong cash conversion, underpinned by strategic investments in data centre capacity and AI capabilities.

Macquarie Technology Group has reported its eleventh consecutive year of EBITDA growth, driven by strategic investments in data centre infrastructure and AI capabilities. The company is advancing its IC3 SuperWest project and has secured land for a new Sydney data centre campus.

Macquarie Technology Group reported modest revenue and profit growth for FY25, underpinned by a new $450 million undrawn debt facility aimed at expanding its data centre portfolio. The company’s strategic investments include the on-time construction of IC3 SuperWest and a $240 million option to acquire land for a new Sydney campus.

NextEd Group Limited reported a 13.9% revenue decline to $95.9 million for FY25 but achieved a 53% improvement in net loss after tax, driven by cost savings and operational efficiencies. The company’s strategic repositioning includes leadership changes and expanded vocational offerings.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.

Gryphon Capital Income Trust (ASX, GCI) reported a robust fiscal 2025 with a 41.65% jump in revenue and a substantial capital raise to expand its RMBS/ABS portfolio. The Trust’s net assets topped $1 billion, reflecting strong investor confidence and strategic growth.

Shriro Holdings reported a 13.6% revenue decline to $103.3 million in FY25 but delivered a 5.5% rise in EBITDA and an 8.7% increase in net profit after tax. The company completed a $15 million share buy-back and deferred its final dividend as it explores alternative capital uses.

Australian Unity Limited reports a strong FY2025 financial turnaround with $136.2 million Adjusted EBITDA, driven by a multi-year transformation program focused on portfolio reshaping and technology integration.

Flight Centre Travel Group has launched a A$450 million convertible notes offering due 2032, aiming to repurchase up to A$325 million of existing notes and support its growth ambitions with extended debt maturity.

GenusPlus Group Ltd has delivered record FY2025 financial results, driven by strong contract wins and strategic acquisitions, positioning itself as a key player in Australia’s energy transition. The company forecasts robust earnings growth for FY2026 backed by a $2 billion orderbook.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.